Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX

NOVAVAX, INC.

(NVAX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
86.4(c) 86.55(c) 93.98(c) 95.33(c) 102.6(c) Last
3 249 891 2 561 016 6 557 407 3 101 622 3 764 882 Volume
-3.90% +0.17% +8.58% +1.44% +7.63% Change
More quotes
Financials (USD)
Sales 2020 550 M - -
Net income 2020 -310 M - -
Net cash position 2020 465 M - -
P/E ratio 2020 -17,6x
Yield 2020 -
Sales 2021 3 133 M - -
Net income 2021 984 M - -
Net cash position 2021 736 M - -
P/E ratio 2021 7,06x
Yield 2021 -
Capitalization 4 875 M 4 875 M -
EV / Sales 2020 8,02x
EV / Sales 2021 1,32x
Nbr of Employees 522
Free-Float 97,6%
More Financials
Company
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline... 
More about the company
Notations Surperformance© of Novavax, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about NOVAVAX, INC.
01:52pHow will Canada's COVID-19 vaccine program work?
RE
06:06aEXPLAINER : When and how will COVID-19 vaccines become available?
RE
11/20Pfizer, BioNTech Ask FDA to Authorize Their Covid-19 Vaccine -- 2nd Update
DJ
11/20Pfizer, BioNTech Ask FDA to Authorize Their Covid-19 Vaccine -- 2nd Update
DJ
11/20Pfizer, BioNTech to Seek Authorization of Covid-19 Vaccine Friday -- Update
DJ
11/20Pfizer to Seek Authorization of Covid-19 Vaccine Friday
DJ
11/18PFIZER, MODERNA COVID-19 VACCINES MA : U.S. official
RE
11/18Pfizer Says Covid Vaccine Is 95% Effective in Final Data, Will Seek Authoriza..
DJ
11/18Pfizer's Covid-19 Vaccine 95% Effective in Final Results, Company to Seek App..
DJ
11/13Canada bets on imports as home-grown COVID-19 vaccine heads to large-scale tr..
RE
11/13SINOVAC BIOTECH : Indonesia to start mass COVID-19 vaccination this year - Presi..
RE
11/12NOVAVAX : FDA grants Fast Track Designation to Novavax COVID-19 vaccine candidat..
AQ
11/12NOVAVAX : Why I volunteered for a COVID-19 vaccine trial
RE
11/12India's Serum says made 40 million doses of AstraZeneca's COVID vaccine, to m..
RE
11/11Pfizer CEO Joins Host of Executives at Covid-19 Vaccine Makers in Big Stock S..
DJ
More news
News in other languages on NOVAVAX, INC.
11/19NOVAVAX : Coronavirus-La Commission européenne réfléchit à une levée coordonnée ..
11/18COVID-19 : onze candidats vaccins en dernière phase d'essais sur l'homme
11/16Des idées d'ETF pour miser sur le retour en grâce des valeurs moyennes
11/15PANDÉMIE : des patrons de laboratoires s'enrichissent et suscitent des questions
10/29Takeda relève ses objectifs de bénéfices, s'associe avec Moderna sur le Covid..
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 186,20 $
Last Close Price 95,33 $
Spread / Highest target 134%
Spread / Average Target 95,3%
Spread / Lowest Target -21,3%
EPS Revisions
Managers
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
Gregory F. Covino Chief Financial Officer & Executive Vice President
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.2,261.31%4 875
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.82.32%36 284
IQVIA HOLDINGS INC.11.32%32 977
SEAGEN INC.44.08%29 684